Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
暂无分享,去创建一个
T. Chou | C. Chiu | Ling-Hui Li | Chun-Yen Hsiao | C. Tzen | Kuo‐Ting Chang | Yuh-Min Chen | R. Perng | S. Tsai | Chun-Ming Tsai | C. Hsiao | C. Tsai
[1] T E Walsh,et al. Reporting results. , 1969, Archives of otolaryngology.
[2] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[3] Y. Shimosato,et al. Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.
[4] Y. Ko,et al. Chinese food cooking and lung cancer in women nonsmokers. , 2000, American journal of epidemiology.
[5] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[6] I. Rosenberg,et al. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. , 2000, American journal of epidemiology.
[7] G. Sheu,et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. , 2001, Cancer research.
[8] J. Minna,et al. Focus on lung cancer. , 2002, Cancer cell.
[9] R. Matthay,et al. Epidemiology, etiology, and prevention of lung cancer. , 2002, Clinics in chest medicine.
[10] F. Bray,et al. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. , 2003, The Lancet. Oncology.
[11] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[14] R. Roskoski. The ErbB/HER receptor protein-tyrosine kinases and cancer*1 , 2004 .
[15] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[16] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[17] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Kerbel,et al. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. , 2004, International journal of radiation oncology, biology, physics.
[19] G. Scagliotti,et al. The Biology of Epidermal Growth Factor Receptor in Lung Cancer , 2004, Clinical Cancer Research.
[20] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[21] Ping Yang,et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. , 2004, The Annals of thoracic surgery.
[22] Roy S Herbst,et al. Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.
[23] Mengzhao Wang,et al. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme , 2004, BMC Cancer.
[24] F. Hirsch,et al. Bronchioloalveolar Carcinoma , 2004, Clinical Cancer Research.
[25] Shih-Feng Tsai,et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.
[26] Joon-Oh Park,et al. Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[27] P. Kvale,et al. Smoking and lung cancer survival: the role of comorbidity and treatment. , 2004, Chest.
[28] Joachim Herz,et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? , 2004, Trends in molecular medicine.
[29] Gefitinib ( ZD 1839 ) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer , 2004 .
[30] R. Roskoski. The ErbB/HER receptor protein-tyrosine kinases and cancer. , 2004, Biochemical and biophysical research communications.
[31] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Chiu,et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. , 2005, Lung cancer.
[33] F. Khuri,et al. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. , 2006, Oncology.